A molecular simplification approach of previously reported 2-arylpyrazolo[3,4-c]quinolin-4-ones was applied to design 2-arylpyrazolo[4,3-d]pyrimidin-7-one derivatives as new human A3 adenosine receptor antagonists. Substituents with different lipophilicity and steric hindrance were introduced at the 5-position of the bicyclic scaffold (R5 = H, Me, Et, Ph, CH2Ph) and on the 2-phenyl ring (OMe, Me). Most of the synthesized derivatives were highly potent hA3 adenosine receptor antagonists, the best being the 2-(4-methoxyphenyl)pyrazolo[4,3-d]pyrimidin-7-one (Ki = 1.2 nM). The new compounds were also highly selective, being completely devoid of affinity toward hA1, hA2A, and hA2B adenosine receptors. On the basis of the recently published human A2A receptor crystallographic information, we propose a novel receptor-driven hypothesis to explain both A3 AR affinity and A3 versus A2A selectivity profiles of these new antagonists.

2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a New Scaffold To Obtain Potent and Selective Human A(3) Adenosine Receptor Antagonists: New Insights into the Receptor-Antagonist Recognition (dagger).

VARANI, Katia;VINCENZI, Fabrizio;BOREA, Pier Andrea;
2009

Abstract

A molecular simplification approach of previously reported 2-arylpyrazolo[3,4-c]quinolin-4-ones was applied to design 2-arylpyrazolo[4,3-d]pyrimidin-7-one derivatives as new human A3 adenosine receptor antagonists. Substituents with different lipophilicity and steric hindrance were introduced at the 5-position of the bicyclic scaffold (R5 = H, Me, Et, Ph, CH2Ph) and on the 2-phenyl ring (OMe, Me). Most of the synthesized derivatives were highly potent hA3 adenosine receptor antagonists, the best being the 2-(4-methoxyphenyl)pyrazolo[4,3-d]pyrimidin-7-one (Ki = 1.2 nM). The new compounds were also highly selective, being completely devoid of affinity toward hA1, hA2A, and hA2B adenosine receptors. On the basis of the recently published human A2A receptor crystallographic information, we propose a novel receptor-driven hypothesis to explain both A3 AR affinity and A3 versus A2A selectivity profiles of these new antagonists.
Lenzi, O.; Colotta, V.; Catarzi, D.; Varano, F.; Poli, D.; Filacchioni, G.; Varani, Katia; Vincenzi, Fabrizio; Borea, Pier Andrea; Paoletta, S.; Morizzo, E.; Moro, S.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/1380418
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact